Literature DB >> 8406734

Clostridium difficile colitis and diarrhea.

C Pothoulakis1, J T LaMont.   

Abstract

Clostridium difficile is now regarded as the most prevalent nosocomial pathogen, infecting as many as a quarter of hospitalized patients. The pathophysiology of infection with this unusual enteric pathogen involves alteration of the normal enteric flora by antibiotics, ingestion of spores, and colonization by C. difficile. The organism then releases potent exotoxins that produce an inflammatory colitis and diarrhea. A spectrum of host responses occurs, ranging from the asymptomatic carrier state to life-threatening pseudomembranous colitis. Effective therapy with vancomycin or metronidazole is available, but relapses occur in 15% to 20% of patients and may necessitate multiple courses of therapy.

Entities:  

Mesh:

Year:  1993        PMID: 8406734

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  20 in total

1.  Practical considerations in the use of outpatient antimicrobial therapy for musculoskeletal infections.

Authors:  Camelia E Marculescu; Elie F Berbari; J Robert Cantey; Douglas R Osmon
Journal:  Mayo Clin Proc       Date:  2012-01       Impact factor: 7.616

2.  Clostridium difficile toxin A induces the release of neutrophil chemotactic factors from rat peritoneal macrophages: role of interleukin-1beta, tumor necrosis factor alpha, and leukotrienes.

Authors:  M F Rocha; M E Maia; L R Bezerra; D M Lyerly; R L Guerrant; R A Ribeiro; A A Lima
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

3.  The insect peptide coprisin prevents Clostridium difficile-mediated acute inflammation and mucosal damage through selective antimicrobial activity.

Authors:  Jin Ku Kang; Jae Sam Hwang; Hyo Jung Nam; Keun Jae Ahn; Heon Seok; Sung-Kuk Kim; Eun Young Yun; Charalabos Pothoulakis; John Thomas Lamont; Ho Kim
Journal:  Antimicrob Agents Chemother       Date:  2011-08-01       Impact factor: 5.191

4.  GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis.

Authors:  C B Kurtz; E P Cannon; A Brezzani; M Pitruzzello; C Dinardo; E Rinard; D W Acheson; R Fitzpatrick; P Kelly; K Shackett; A T Papoulis; P J Goddard; R H Barker; G P Palace; J D Klinger
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

5.  [Antibiotic induced diarrhea and pseudomembranous colitis].

Authors:  C Greb; T Kalem; T Kälble
Journal:  Urologe A       Date:  2002-12-19       Impact factor: 0.639

6.  Toxin binding of tolevamer, a polyanionic drug that protects against antibiotic-associated diarrhea.

Authors:  William Braunlin; Qiuwei Xu; Patrick Hook; Richard Fitzpatrick; Jeffrey D Klinger; Robert Burrier; Caroline B Kurtz
Journal:  Biophys J       Date:  2004-07       Impact factor: 4.033

7.  A new formulation of tolevamer, a novel nonantibiotic polymer, is safe and well-tolerated in healthy volunteers: a randomized phase I trial.

Authors:  Jennifer Peppe; Andrew Porzio; David M Davidson
Journal:  Br J Clin Pharmacol       Date:  2008-03-13       Impact factor: 4.335

8.  Recombinant single-chain variable fragment antibodies directed against Clostridium difficile toxin B produced by use of an optimized phage display system.

Authors:  Xiao K Deng; Lance A Nesbit; K John Morrow
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

Review 9.  Metronidazole. A therapeutic review and update.

Authors:  C D Freeman; N E Klutman; K C Lamp
Journal:  Drugs       Date:  1997-11       Impact factor: 9.546

10.  Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies.

Authors:  Sandra Dial; Khalid Alrasadi; Chantal Manoukian; Allen Huang; Dick Menzies
Journal:  CMAJ       Date:  2004-07-06       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.